PRECISION THERAPEUTICS FOR NEURODEGENERATION

Rethinking neurodegeneration through cholesterol biology

ACATbio is developing selective ACAT1 inhibitors designed to restore intracellular cholesterol balance and address interconnected drivers of neurodegenerative disease.

About

The Problem:

Cholesterol dysregulation drives disease progression

Diagram showing the cycle of disease progression from cholesterol accumulation to cell death, including risk factors such as APOE4, TREM2, ABCA7, and CLU.

The Solution:

Restore cholesterol balance by targeting ACAT1

A flowchart illustrating how ACAT1 (SOAT1) inhibition can restore cholesterol balance, reduce amyloid and tau pathology, suppress neuroinflammation, and restore BBB integrity.

ACATbio Team:

Headshot of Jennifer Vella, PhD, with text describing her as a translational immunologist co-founder, experienced in biotech and drug development, and a leader in preclinical program design.
Headshot of Taylor Harned, PhD, PMP with text describing him as biotech leader with lipid biology experience, including prior work studying ACAT1 (SOAT1) mechanisms and therapeutics.
Headshot of Catherine (Cathy) Chang, PhD, with text attributing to her the discovery and mechanistic elucidation of ACAT1 (SOAT1)
Headshot of TY Chang, PhD, with text describing him as a leader in the ACAT1 (SOAT1), cholesterol metabolism, and Alzheimer's disease fields.